March 25, 2021
More and more healthcare professionals are incorporating Hyperbaric Oxygen Therapy into their medical practice. This is the result of the development of technologies such as Biobarica and the effort in the communication and development of scientific evidence.
In recent years, Hyperbaric Oxygen Therapy has become an essential tool in the treatment of different pathologies related to pain, wounds, and rehabilitation. This is due to the development of new technologies that have accused the installation and operation of Hyperbaric Oxygen units in doctors' offices, clinics, and healthcare institutions. Biobarica is the leading company in the most accessible and friendly technology for either patients and professionals.
This Argentinian company is present in more than 35 countries where it works to improve health, digitize medical care and improve patient outcomes. The company stands out for having the largest network of hyperbaric treatment centers where multidisciplinary professionals converge to provide therapy and exchange knowledge and clinical cases. It also manufactures the Revitalair 430 Hyperbaric Chamber, a medical device in which the patient breathes high concentrations of oxygen through a mask in a pressurized environment at 1.45 ATA.
Hyperbaric Oxygen Therapy in this equipment generates hyperoxia (increased oxygen in the blood plasma) which acts on all tissues of the body systematically. Hyperoxia in itself produces beneficial physiological effects to treat pathologies of different medical specialties:
The effectiveness of Hyperbaric Oxygen Therapy has been widely proven. Since the 1940s, more than 19,000 scientific papers have been published on the uses and benefits of this treatment in different pathologies that go beyond decompression sickness and carbon monoxide poisoning, for which it was originally indicated.
As a result, more and more healthcare professionals are incorporating Hyperbaric Oxygen Therapy into their practice and providing their patients with a safe, efficient, and non-invasive treatment that accompanies and boosts the success of other conventional therapies.
Although Hyperbaric Oxygenation has more than 200 years of history, it was traditionally used with large rigid equipment with complex installation requirements. Over the years, technology has evolved and the usage of easy-to-operate and risk-free equipment is becoming more and more popular.
"Revitalair® 430 is currently the safest and most comfortable single-seat hyperbaric chamber. It stands out for its design and high-quality materials. It can be assembled quickly and can be operated by anyone with the training provided by Biobarica. This represents a big change in the market, as it makes the use of the Hyperbaric Chamber in medical practice at different levels more accessible and simple", explains Ivo Teler, Commercial Director of Biobarica.
The company also provides software infrastructure, data analysis, and support tools that help healthcare professionals to treat and monitor their patients in the best possible way. In addition, it provides training and medical-scientific, technical, and commercial support to operate a Hyperbaric Medicine Unit efficiently and cost-effectively.
"As global innovators in medical technology we are focused on expanding the supply of high-quality Hyperbaric Oxygen Therapy through our Hyperbaric Chambers. We have all the international certifications as a medical device, including ANMAT, CE, FDA, and others, but the most interesting thing about Biobarica is that over the years we have developed whole know-how that gives a lot of value to our activity," says Claudio.
Hyperbaric Oxygen Therapy has not only evolved in terms of technology but also its uses and applications. It is now an important ally in the treatment of severe COVID-19 patients. This is because the severity of the new coronavirus is related to the level of hypoxemia and its duration, respiratory failure, and its persistence despite normobaric oxygen supply. Hyperbaric oxygen helps to reverse hypoxemia and has a powerful anti-inflammatory effect by regulating inflammatory cytokines and reducing exudate.
Recently 36 patients with COVID-19 were part of a successful multicentre protocol conducted in three hospitals in Buenos Aires with Revitalair Hyperbaric Chambers. The researchers reported a significant improvement after two sessions and the final saturation in the treatment group was on average higher than 93.
Post-Covid sequels and their clinical manifestation are variable and are still under study. Cardiorespiratory damage compatible with fibrosis and some neurological findings due to sustained hypoxemia, inflammation, and the patient's immune response is known.
Hyperbaric therapy has an anti-inflammatory effect that can reverse cardiac and/or pulmonary fibrosis and inflammation and improve hypoxemia even after the infection has resolved. In addition, it modulates the patient's immune response. Furthermore, the increased neuroplasticity achieved with hyperbaric oxygen may be useful in the rehabilitation of neurological consequences caused by sustained hypoxia in nervous and muscular tissue.
For all these reasons, incorporating the Biobarica Hyperbaric Treatment System is a safe, effective and innovative solution to improve the recovery of patients with different pathologies. It is a technology that makes a difference in the care of doctors' offices, clinics, or health institutions and encourages the growth of professionals at the latest of available treatments.